Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04815785

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04815785
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04815785. Allocation not applicable; no masking; primary purpose treatment. Start 2017-09-22 (actual); primary completion 2020-05-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
Condition
Aortic Stenosis
Intervention (Device)
TaurusOne® transcatheter aortic valve replacement system
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd. (class: industry)
Collaborator
Fu Wai Hospital, Beijing, China (class: other)
Collaborator
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)
Collaborator
West China Hospital (class: other)
Collaborator
General Hospital of Shenyang Military Region (class: other)
Collaborator
The Second Affiliated Hospital of Harbin Medical University (class: other)
Collaborator
Second Xiangya Hospital of Central South University (class: other)

Record details

Record id
cardio:ct-nct04815785
Content hash
24f363241f271ef5ee2a8c41a8adde4b5d62724dd49132429d47437850dd35c2